SUN-820 The Impact of GLP-1 Agonists on the Development of Body Dysmorphic Disorder

Abstract Disclosure: K. Suhas: None. A. Royfman: None. S. King: None. K. Speiker: None. K. Szymanski: None. Background: Glucagon-like peptide (GLP-1) agonists, initially developed for diabetes management have gained increasing popularity for obesity treatment and weight loss. While these drugs offer weight loss benefits, they can also trigger or worsen Body Dysmorphic Disorder (BDD) in vulnerable individuals. BDD is characterized by an obsessive preoccupation with perceived physical flaws. For those predisposed to this condition, rapid weight loss may heighten body dissatisfaction, leading to a harmful cycle of fixation on appearance. This study explores the relationship between GLP-1 agonist use and the emergence of BDD, emphasizing the psychological implications of weight loss medications. Methods: Data for this study was sourced from TriNetX, a global federated health research network, analyzing de-identified electronic health record data. Cohorts were defined by patients prescribed GLP-1 agonists and classified into two groups: those who developed BDD and those who did not. We excluded patients with metabolic syndrome or diabetes. Statistical analysis compared demographic, psychiatric, procedural, and medication data between the two cohorts. Results: A total of 416,503 patients were evaluated, with 132 developing BDD after receiving GLP-1 agonists. Patients who developed BDD were younger (mean age 41 vs. 51 years old) and had a higher prevalence of psychiatric comorbidities, including depression (70% vs. 27%) and eating disorders (39% vs. 2%) compared to those without BDD. Aesthetic surgeries, including lipectomy and abdominoplasty, were more common in the BDD cohort (8% vs. 0%). Antidepressant prescriptions were significantly higher among the BDD group (83% vs. 56%), indicating a notable association between psychiatric treatment and BDD development. Conclusion: This study reveals the development of BDD in those prescribed a GLP-1 agonist use have higher rates of pre-existing psychiatric vulnerabilities compared to those who do not develop BDD. The rising popularity of GLP-1 agonists for weight loss, combined with societal pressures surrounding body image, may trigger or exacerbate mental health issues. Clinicians should consider pre-existing psychiatric conditions and provide closer monitoring for patients prescribed GLP-1 agonists to mitigate the risk of developing BDD and related mental health disorders. Presentation: Sunday, July 13, 2025